Page 55 - Read Online

Tanasanvimon. J Cancer Metastasis Treat 2018;4:57 I http://dx.doi.org/10.20517/2394-4722.2018.38 Page 9 of 11

10. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. Wild-type KRAS is required for panitumumab efficacy in patients with
metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
11. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil,
leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic
colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
13. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
N Engl J Med 2013;369:1023-34.
14. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of
K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Oncologist 2009;14:22-8.
15. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, et al. Impact of KRAS and BRAF gene mutation status on outcomes from
the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J
Clin Oncol 2011;29:2675-82.
16. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, et al. KRAS and BRAF mutations in advanced colorectal cancer are
associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol
2009;27:5931-7.
17. Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab
in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014;20:744-53.
18. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, et al. Addition of cetuximab to chemotherapy as first-line treatment
for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer
2012;48:1466-75.
19. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, et al. Massively parallel tumor multigene sequencing to evaluate response to
panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-12.
20. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with
KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol
2013;14:749-59.
21. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, et al. Predictive role of BRAF mutations in patients with advanced
colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51:587-94.
22. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, et al. Meta-analysis of BRAF mutation as a predictive biomarker of
benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015;112:1888-94.
23. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive
markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol
2013;18:670-7.
24. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, et al. Increased detection sensitivity for KRAS mutations enhances the
prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011;17:4901-14.
25. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG
expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011;6:e15980.
26. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the
efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Lancet Oncol 2010;11:753-62.
27. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, et al. PI3KCA/PTEN deregulation contributes to impaired responses to
cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
28. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and
PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014;53:852-64.
29. Mohamed A, Twardy B, AbdAllah N, Akhras A, Ismail H, et al. Clinical impact of PI3K/BRAF mutations in RAS wild metastatic colorectal
cancer: meta-analysis results. J Gastrointest Cancer 2018; doi: 10.1007/s12029-018-0062-y.
30. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, et al. Differential expression of epidermal growth factor-related proteins in human
colorectal tumors. Proc Natl Acad Sci U S A 1991;88:7792-6.
31. Li XD, Miao SY, Wang GL, Yang L, Shu YQ, et al. Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with
clinicopathological characteristics. Onkologie 2010;33:353-8.
32. Chayangsu C, Khunsri S, Sriuranpong V, Tanasanvimon S. The correlations between serum amphiregulin and other clinicopathological
factors in colorectal cancer. J Gastrointest Oncol 2017;8:980-4.
33. Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, et al. Amphiregulin and epiregulin mRNA expression in primary colorectal
cancer and corresponding liver metastases. BMC Cancer 2012;12:88.
34. Oliveras-Ferraros C, Cufi S, Queralt B, Vazquez-Martin A, Martin-Castillo B, et al. Cross-suppression of EGFR ligands amphiregulin
and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer
2012;106:1406-14.
35. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, et al. Autocrine action of amphiregulin in a colon carcinoma cell line and
immunocytochemical localization of amphiregulin in human colon. J Cell Biol 1992;118:741-51.
36. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, et al. Expression of epiregulin and amphiregulin and K-ras mutation
status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.